Since resistance to oxaliplatin treatment is one of the main reason for the failure of chemotherapy in CRC, the findings of miR-503-5p as a contributing factor of MDR and the certification of the p53/miR-503-5p/PUMA signaling axis should help design strategies to increase efficacy of oxaliplatin treatment of CRC. This evidence concerns the gene TP53 and colorectal carcinoma.